the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
January 26, 2020 – Common belief holds that differences in genes (i.e., allelic variants) in combination with differing frequencies of such allelic variants in populations of different ethnic background may explain the differences in the frequency and/or severity of overt …
Degree of African ancestry may influence gene expression levels Read more »
Through a new boxed warning, the FDA is alerting healthcare professionals about a subgroup of patients who cannot effectively metabolize the anti-platelet drug Clopidogrel [Plavix]. These patients, called “poor metabolizers,” have little or no activity of the liver enzyme CYP2C19, …
Reduced Effect from Clopidogrel [Plavix] in “Poor Metabolizer” Patients Read more »
March 17, 2010 – The U.S. Food and Drug Administration (FDA) has added a Boxed Warning to the label for Clopidogrel [Plavix], the anti-blood clotting medication. The Boxed Warning is about patients who do not effectively metabolize the drug (i.e. …
November 17, 2009 – Today, the US Food and Drug Administration (FDA) informed on new data showing that the proton pump inhibitor (PPI) Omeprazole [Prilosec] or [Prilosec OTC] reduces the anti-blood clotting effect of Clopidogrel [Plavix] by almost half when …